Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
Serina Therapeutics reported its Q1 2024 financial results, highlighting significant developments. The company is advancing its lead drug candidate, SER-252, for advanced Parkinson’s Disease, with plans to submit an IND application in 2025. Serina completed its merger with AgeX Therapeutics and appointed Dr. Simba Gill as Executive Chairman. Financially, Serina increased its line of credit by $2.4 million and received an additional $525,000 in May 2024. Cash and equivalents totaled $8.8 million, with a net loss of $9.4 million for Q1 2024. Revenues were $5,000, and operating expenses increased to $2.3 million from $1 million in the same period in 2023. The company expressed concerns about its ability to meet financial obligations over the next year.
- Advancement of lead drug candidate SER-252 for advanced Parkinson’s Disease.
- Completion of merger with AgeX Therapeutics.
- Appointed Dr. Simba Gill as Executive Chairman to guide strategic growth.
- Increased line of credit by $2.4 million, with an additional $525,000 received in May 2024.
- Cash, cash equivalents and restricted cash totaled $8.8 million as of March 31, 2024.
- Net loss of $9.4 million for Q1 2024 compared to a net income of $1.7 million in Q1 2023.
- Revenue decline to $5,000 from $30,000 in the same period in 2023.
- Operating expenses increased to $2.3 million from $1 million in Q1 2023.
- Substantial doubt about the company's ability to meet financial obligations within the next year.
- Increased debt, with $10.4 million owed to Juvenescence
Serina Therapeutics’ financial results for Q1 2024 provide critical insights into the company’s operational health. The company's net loss of
The progression of SER-252, Serina's lead drug candidate, is noteworthy for stakeholders. Aiming for an IND application and a Phase 1 clinical trial by 2025 highlights the company’s strategic focus on addressing advanced Parkinson's Disease. This long-term goal may appeal to investors interested in biotech innovations and potential breakthroughs in neurological treatments. However, the timeline suggests that revenue generation from SER-252 is still years away, which could affect short-term investor interest. The recent merger with AgeX Therapeutics and the appointment of Dr. Simba Gill as Executive Chairman potentially provide a robust leadership structure and new strategic directions. While mergers can create synergies and open new markets, they also carry integration risks. Dr. Gill’s extensive experience could be pivotal in navigating these challenges and driving future growth. Still, the market reaction will depend heavily on the successful integration of the two companies and the tangible advancements in their combined pipelines.
The strategic decisions and developments highlighted by Serina Therapeutics emphasize their commitment to innovation and growth. Advancing SER-252 for Parkinson’s Disease shows a clear pathway to addressing significant unmet medical needs. However, this also places the company in a competitive landscape where larger, more established biotech firms are also vying for market share. The proprietary POZ Platform™ drug delivery technology could set Serina apart if proven effective and scalable. The completion of the merger with AgeX Therapeutics and subsequent leadership changes suggest a transformative phase for the company. Dr. Gill’s appointment as Executive Chairman could enhance strategic direction and operational efficiency, leveraging his past successes. Yet, the substantial focus on early-stage pipeline development means that investors must be prepared for a high-risk, high-reward scenario, typical of clinical-stage biotech companies.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended March 31, 2024 and provided business highlights.
Recent Highlights
| ● | Advancement of SER-252. The Company is advancing its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease. The Company anticipates submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration with plans to initiate a Phase 1 clinical trial in 2025. | |
| ● | Completion of merger with AgeX Therapeutics. The Company closed its merger with a wholly owned subsidiary of AgeX Therapeutics, Inc. The management team of the combined company is led by Steven Ledger as Interim Chief Executive Officer. The combined company began trading on the NYSE American market under the ticker symbol “SER” on March 27, 2024. | |
| ● | Appointment of Dr. Simba Gill as Executive Chairman. Dr. Gill brings a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key roles at Maxygen, Systemix, Boehringer Mannheim and Celltech. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London. Dr. Gill will play a pivotal role in guiding Serina through its next phase of growth and development, leveraging his expertise to drive strategic expansion initiatives. |
Liquidity and Capital Resources
Increase in Line of Credit
On March 26, 2024, the Company’s secured, convertible line of credit from Juvenescence Limited was increased by
On May 8, 2024, the repayment date of the Company’s borrowings under the Juvenescence line of credit was extended from May 9, 2024 to December 31, 2024 and the line of credit increased by an additional
Balance Sheet Information
Cash, cash equivalents, and restricted cash totaled
First Quarter 2023 Operating Results
Revenues: Revenues comprised entirely of grant revenues in the amount of
Operating expenses: Operating expenses for the three months ended March 31, 2024 were
Research and development expenses for the three months ended March 31, 2024 increased by approximately
General and administrative expenses for the three months ended March 31, 2024 increased by
Other expense, net: Net other expense for the three months ended March 31, 2024 is primarily comprised of
Net loss: The net loss for the three months ended March 31, 2024 was
Going Concern Considerations
As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), the Company evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on the Company’s most recent projected cash flows, the Company believes that its cash and cash equivalents and the additional
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.
About the POZ Platform™
Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Serina’s POZ PlatformTM delivery technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of challenging small molecules, while addressing the limitations of PEG (polyethylene glycol) and other biocompatible polymers. In addition, our POZ PlatformTM partners are at the forefront in advancing lipid nanoparticle (LNP) delivery technology to develop novel RNA therapeutics. Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; uncertainties regarding the impact of COVID-19 on Serina’s business, operations and financial results; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC.
The Information contained in this release Is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
SERINA THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value amounts)
(unaudited)
| March 31, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 8,706 | $ | 7,619 | ||||
| Accounts and grants receivable, net | 65 | - | ||||||
| Prepaid expenses and other current assets | 166 | - | ||||||
| Total current assets | 8,937 | 7,619 | ||||||
| Restricted cash | 50 | - | ||||||
| Property and equipment, net | 564 | 573 | ||||||
| Right of use assets - operating leases | 627 | 666 | ||||||
| Right of use assets - finance leases | 104 | 110 | ||||||
| Intangible assets, net | 574 | - | ||||||
| TOTAL ASSETS | $ | 10,856 | $ | 8,968 | ||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFFERED STOCK, AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 4,013 | $ | 1,163 | ||||
| Loans due to Juvenescence, net of debt issuance costs | 9,746 | - | ||||||
| Related party payables, net | 66 | - | ||||||
| Current portion of operating lease liabilities | 207 | 214 | ||||||
| Current portion of finance lease liabilities | 24 | 36 | ||||||
| Other current liabilities | 3 | - | ||||||
| Total current liabilities | 14,059 | 1,413 | ||||||
| Loans due to Juvenescence | 693 | - | ||||||
| Convertible promissory notes, at fair value | - | 2,983 | ||||||
| Operating lease liabilities, net of current portion | 413 | 461 | ||||||
| Finance lease liabilities, net of current portion | - | 1 | ||||||
| TOTAL LIABILITIES | 15,165 | 4,858 | ||||||
| Commitments and contingencies | ||||||||
| Redeemable Convertible Preferred Stock: | ||||||||
| Redeemable convertible preferred stock, | - | 36,404 | ||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock, | - | - | ||||||
| Common stock, | 1 | 25 | ||||||
| Additional paid-in capital | 1,125 | 858 | ||||||
| Accumulated deficit | (5,435 | ) | (33,177 | ) | ||||
| Total stockholders’ deficit | (4,309 | ) | (32,294 | ) | ||||
| TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT | $ | 10,856 | $ | 8,968 | ||||
SERINA THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except par value amounts)
(unaudited)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| REVENUES | ||||||||
| Grant revenues | $ | 5 | $ | 30 | ||||
| Total revenues | 5 | 30 | ||||||
| OPERATING EXPENSES | ||||||||
| Research and development | 1,106 | 399 | ||||||
| General and administrative | 1,220 | 593 | ||||||
| Total operating expenses | 2,326 | 992 | ||||||
| Loss from operations | (2,321 | ) | (962 | ) | ||||
| OTHER INCOME (EXPENSE), NET: | ||||||||
| Interest expense, net | (99 | ) | (86 | ) | ||||
| Fair value inception adjustment on convertible promissory note | - | 2,240 | ||||||
| Change in fair value of convertible promissory notes | (7,017 | ) | 294 | |||||
| Change in fair value of warrants | - | 172 | ||||||
| Total other income (expense), net | (7,116 | ) | 2,620 | |||||
| NET INCOME (LOSS) | $ | (9,437 | ) | $ | 1,658 | |||
| NET EARNINGS (LOSS) PER COMMON SHARE: | ||||||||
| BASIC | $ | (3.38 | ) | $ | 0.77 | |||
| DILUTED | $ | (3.38 | ) | $ | 0.20 | |||
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | ||||||||
| BASIC | 2,790 | 2,167 | ||||||
| DILUTED | 2,790 | 8,569 | ||||||
For inquiries, please contact:
Investor.relations@serinatherapeutics.com
(256) 327-9630
FAQ
What are the key highlights from Serina Therapeutics' Q1 2024 financial results?
What is the status of Serina Therapeutics' lead drug candidate SER-252?
How did Serina Therapeutics' merger with AgeX Therapeutics impact the company?
What were Serina Therapeutics' financial results for Q1 2024?
What financial concerns does Serina Therapeutics have for the upcoming year?
What is Serina Therapeutics' current cash position?
How much does Serina Therapeutics owe to Juvenescence ?
